Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial
5 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
Evidence dossier
Intelligence passport
Measured timeline
-
Detected
-
Latest coverage observed
-
Peak measured velocity
-
Evidence threshold reached
Coverage (5)
-
Capricor’s DMD Therapy Gets Lancet Backing Ahead Of August FDA ShowdownYahoo Finance · 111d ago
-
FDA adcomm shoots down Capricor's Duchenne cell therapy after meeting marked by statistical disputeFierce Biotech · 111d ago
-
FDA panel votes against Capricor's Duchenne heart disease therapyReuters · 111d ago
-
-
What happened
- Velocity & Diffusion: Coverage exploded across 5 distinct news outlets with 5 published articles, achieving a live velocity of 3.
- Primary Driver: 5 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
"Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by Archynetys so far.
Outlets currently covering the story include Yahoo Finance, Fierce Biotech, Reuters and STAT. Archynetys measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
Synthesized from multi-source international reporting and live coverage telemetry under Archynetys open intelligence methodology.
Generated by Archynetys's extractive engine from coverage metadata only — no AI-written claims. Updated 109d ago.
Questions people are asking
Why is "Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystroph" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst Archynetys classifies as a trend.
How does Archynetys measure this trend?
Archynetys scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
How do you expect this trend to evolve over the next 24 hours?
Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.
Topics
Related trends
FDA staff flags data concerns about Capricor's therapy; shares plunge
Capricor Therapeutics shares are plunging after FDA staff disputed the company's claims regarding Phase 3 success for its DMD cell therapy.
Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug
Capricor Therapeutics shares plunged after FDA staff flagged data and efficacy concerns regarding its Duchenne heart disease therapy.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.